ATR vs SLGN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: SLGN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ATR and SLGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ATR and SLGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

AptarGroup makes the precision dispensing and drug-delivery systems that sit on top of everyday products: nasal spray and inhaler valves for pharma, pumps and airless systems for fragrance and skincare, and dispensing and non-dispensing closures for food, beverage, personal care, and home care. The company runs three reporting segments (Pharma, Beauty, and Closures), with Pharma generating the bulk of profit thanks to long-cycle, regulated, high-margin drug-delivery contracts. Aptar serves a global customer base and positions itself around active material science and delivery precision rather than commodity packaging.

Full ATR guide

Silgan Holdings Inc. is a leading maker of sustainable rigid packaging for essential consumer goods, operating in three segments: Dispensing and Specialty Closures (pumps, sprayers, triggers, and caps for fragrance, beauty, healthcare, food, and beverage), Metal Containers (steel and aluminum cans for food and pet food), and Custom Containers (custom-designed plastic containers). Metal Containers has historically been about half of sales while Dispensing and Specialty Closures has grown, boosted by acquisitions, to roughly 45% of revenue, giving Silgan a mix of a stable, high-share North American food-can franchise plus a higher-value dispensing business. Because its customers are consumer-staples companies, demand is relatively steady across economic cycles, and most cost inflation (steel, aluminum, resin) is passed through to customers under contract, though often on a lag.

Full SLGN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ATR drivers: High-margin pharma drug delivery; Beauty and consumer recovery.
• SLGN drivers: Dispensing and specialty closures mix shift; Defensive staples demand and cost pass-through.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Core organic sales have been roughly flat, so headline growth has leaned on acquisitions and currency, which is lower-quality growth. For SLGN, the main risk is slow organic growth: Silgan is a mature, capital-intensive packaging supplier, so volume gains are modest and much of the growth story depends on acquisitions and mix shift rather than end-market expansion.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ATR if you believe its drivers more; SLGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ATR and SLGN guides.

ATR. At $125 Aptar trades at about 23 times trailing and 20 times forward earnings, and about 11.5 times EBITDA, a premium to commodity packagers that rests on the pharma franchise and the dividend record. Analysts see 2026 EPS roughly flat at about $5.51 before a rebound to about $6.21 in 2027, so the multiple only looks reasonable if that recovery arrives. The key tension remains paying for quality while organic growth is near flat.

SLGN. Figures are approximate and tied to the asOf date; verify live numbers before acting. At ~$37.85 on October 16, 2026, Silgan trades at about 15x trailing GAAP earnings but only ~9x forward adjusted earnings and ~8.6x EV/EBITDA, cheaper than it was in the summer after a ~17% three-month slide, which leaves it below most slow-growth industrial packaging peers. Leverage and the gap between GAAP and adjusted earnings are part of the discount, so the valuation case leans as much on cash generation, dividend growth, and deleveraging as on earnings expansion. The 13 covering analysts have a mean target of ~$52.

Headline figures (approximate, October 2026): ATR shows revenue (ttm) ~$3.93B (Q2 2026 +6% y/y), q2 2026 sales / adjusted eps ~$1.03B / $1.42 (vs $1.35 est.), margins Gross ~36%, operating ~12.5%, net ~9%, net income (ttm) ~$363M; SLGN shows revenue (ttm) ~$6.68 billion (Q2 2026 ~$1.64 billion, up ~6.8% year over year), net income (ttm) ~$270 million (~4% net margin; operating margin ~10.3%), adjusted eps (q2 2026) ~$0.98 (vs ~$0.96 estimate), 2026 / 2027 consensus eps ~$3.82 / ~$4.09 (adjusted).

ATR and SLGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ATR and SLGN exposure against your real portfolio. It is not an investment adviser.